- Home
- HCC vs ZLAB Comparison
HCC vs ZLAB Comparison
Compare HCC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- ZLAB
- Stock Information
- Founded
- HCC 2015
- ZLAB 2013
- Country
- HCC United States
- ZLAB China
- Employees
- HCC N/A
- ZLAB N/A
- Industry
- HCC Coal Mining
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- ZLAB Health Care
- Exchange
- HCC Nasdaq
- ZLAB Nasdaq
- Market Cap
- HCC 2.5B
- ZLAB 3.5B
- IPO Year
- HCC 2017
- ZLAB 2017
- Fundamental
- Price
- HCC $45.30
- ZLAB $29.24
- Analyst Decision
- HCC Strong Buy
- ZLAB Buy
- Analyst Count
- HCC 5
- ZLAB 4
- Target Price
- HCC $70.25
- ZLAB $47.37
- AVG Volume (30 Days)
- HCC 853.0K
- ZLAB 1.2M
- Earning Date
- HCC 04-30-2025
- ZLAB 05-08-2025
- Dividend Yield
- HCC 0.71%
- ZLAB N/A
- EPS Growth
- HCC N/A
- ZLAB N/A
- EPS
- HCC 2.01
- ZLAB N/A
- Revenue
- HCC $1,319,451,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- HCC N/A
- ZLAB $44.43
- Revenue Next Year
- HCC $26.14
- ZLAB $48.68
- P/E Ratio
- HCC $22.48
- ZLAB N/A
- Revenue Growth
- HCC N/A
- ZLAB 43.72
- 52 Week Low
- HCC $38.00
- ZLAB $15.65
- 52 Week High
- HCC $75.53
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- HCC 42.79
- ZLAB 42.71
- Support Level
- HCC $43.43
- ZLAB $27.61
- Resistance Level
- HCC $47.79
- ZLAB $32.02
- Average True Range (ATR)
- HCC 2.00
- ZLAB 1.23
- MACD
- HCC -0.28
- ZLAB -0.18
- Stochastic Oscillator
- HCC 26.52
- ZLAB 23.41
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.